Key clinical point: Serious adverse events can occur in patients treated only with placebo in cancer clinical trials.
Major finding: The incidence of grade 3-4 placebo adverse events was 18% in cancer clinical trials.
Study details: Systematic review and meta-analysis of 10 randomized, placebo-controlled, double-blind trials.
Disclosures: No conflicts of interest were declared.
Chacón M et al. JAMA Network Open. 2018 Dec 7. doi: 10.1001/jamanetworkopen.2018.5617.
This Week's Must Reads
Must Reads in Renal Cell Carcinoma
First-line avelumab/axitinib for RCC benefits wide range of patients, Choueiri TK et al. GUCS 2019, Abstract 544.